TCGA-OR-A5LH-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.451
- BILE_ACID_METABOLISM+0.375
- OXIDATIVE_PHOSPHORYLATION+0.358
- INTERFERON_GAMMA_RESPONSE+0.355
- FATTY_ACID_METABOLISM+0.348
- KRAS_SIGNALING_DN+0.264
- ADIPOGENESIS+0.215
- PEROXISOME+0.190
- CHOLESTEROL_HOMEOSTASIS+0.188
- PANCREAS_BETA_CELLS+0.174
Top 10 suppressed
- E2F_TARGETS-0.554
- G2M_CHECKPOINT-0.524
- ANGIOGENESIS-0.464
- MITOTIC_SPINDLE-0.422
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.419
- MYC_TARGETS_V1-0.347
- MYC_TARGETS_V2-0.281
- UV_RESPONSE_DN-0.266
- DNA_REPAIR-0.249
- APICAL_JUNCTION-0.198
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1IK-01A-11R-A144-07 | — | B | 0.888 |
| 2 | TCGA-CV-6955-01A-11R-2016-07 | — | — | 0.818 |
| 3 | SRR26320087 | — | — | 0.816 |
| 4 | TCGA-OR-A5J6-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.814 |
| 5 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.808 |
| 6 | 82988 | EPN | Supratentorial EPN | 0.804 |
| 7 | TCGA-CQ-6222-01A-11R-1915-07 | — | — | 0.794 |
| 8 | TCGA-H7-7774-01A-21R-2081-07 | — | — | 0.791 |
| 9 | SRR8518337 | — | F | 0.791 |
| 10 | BS_EHVYJAVA | pilocytic astrocytoma | — | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.451 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.375 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.358 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.355 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.348 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.264 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.215 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.188 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.174 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.132 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.115 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.107 | Idelalisib | — uncovered |
| APOPTOSIS | 0.104 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.101 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.099 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.096 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.095 | Inavolisib | — uncovered |